BCL2L1 and melanoma: Interestingly, EGFR/STAT signaling may differ in human melanoma versus Xiphophorus Xmrk models since inhibition of c-Src kinase activity, but not EGFR, in human melanoma-derived cell lines, downregulates STAT3 signaling and Bcl-xL expression [59].